Skip to main content
Erschienen in:

16.08.2020 | Original Article

High expression of microRNA20b is associated with malignant clinicopathological features and poor prognosis in breast phyllodes tumor

verfasst von: Ting Lei, Lijuan Yin, Hongying Zhang, Bing Wei, Huijiao Chen, Tianjie Pu, Libo Yang, Feng Ye, Zhang Zhang, Hong Bu

Erschienen in: International Journal of Clinical Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

microRNAs, which expound the transcriptional regulation of gene expression, have been validated as prognostic markers in many tumors. The deregulated expression of microRNAs has been shown to aid classification of tumors and predict outcome in many tumors including breast PTs. The aim of our study is to investigate the clinical significance and prognostic value of microRNAs in PTs to identify a biomarker which has the potential for predicting prognosis and target therapy.

Methods

Quantitative real-time PCR (qRT-PCR) was used to detect the expression level of microRNA20b in 123 breast PTs patients. The correlations between the expression of microRNA20b and clinicopathological parameters were investigated. The prognostic significance of microRNA20b was investigated by the Kaplan–Meier survival and Cox proportional hazards regression model.

Results

The expression level of microRNA20b increased with the increase in the tumor grade (p < 0.05). High expression of microRNA20b correlated with stromal overgrowth, marked stromal cellularity, high atypia of stromal cells, infiltrative tumor margin, high mitotic activity, tumor grade, local recurrence and metastasis (p < 0.05). High expression of microRNA20b correlated with the shorter disease-free survival (DFS) (log-rank test, p < 0.001). Multivariate Cox regression analysis showed that microRNA20b was an independent prognostic indicator for breast PTs patients.

Conclusion

The study demonstrated the promising potential of applying microRNA20b as a prognostic biomarker in PT patients.
Literatur
1.
Zurück zum Zitat Krings G, Bean GR, Chen YY (2017) Fibroepithelial lesions: The WHO spectrum. Semin Diagn Pathol 34:438–452CrossRef Krings G, Bean GR, Chen YY (2017) Fibroepithelial lesions: The WHO spectrum. Semin Diagn Pathol 34:438–452CrossRef
2.
Zurück zum Zitat WHO Classification of Tumours Editorial Board (2019) Breast tumours, vol 2, 5th edn. IARC, Lyon, France WHO Classification of Tumours Editorial Board (2019) Breast tumours, vol 2, 5th edn. IARC, Lyon, France
3.
Zurück zum Zitat Zhang Y, Kleer CG (2016) Phyllodes tumor of the breast histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med 140:665–671CrossRef Zhang Y, Kleer CG (2016) Phyllodes tumor of the breast histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med 140:665–671CrossRef
4.
Zurück zum Zitat Noronha Y, Raza A, Hutchins B et al (2011) CD34, CD117, and Ki-67 expression in phyllodes tumor of the breast: an immunohistochemical study of 33 cases. Int J Surg Pathol 19:152–158CrossRef Noronha Y, Raza A, Hutchins B et al (2011) CD34, CD117, and Ki-67 expression in phyllodes tumor of the breast: an immunohistochemical study of 33 cases. Int J Surg Pathol 19:152–158CrossRef
5.
Zurück zum Zitat Vilela MH, de Almeida FM, de Paula GM et al (2014) Utility of Ki-67, CD10, CD34p53, CD117, and mast cell content in the differential diagnosis of cellular fibroadenomas and in the classification of phyllodes tumors of the breast. Int J Surg Pathol 22:485–491CrossRef Vilela MH, de Almeida FM, de Paula GM et al (2014) Utility of Ki-67, CD10, CD34p53, CD117, and mast cell content in the differential diagnosis of cellular fibroadenomas and in the classification of phyllodes tumors of the breast. Int J Surg Pathol 22:485–491CrossRef
6.
Zurück zum Zitat Tan WJ, Cima I, Choudhury Y et al (2016) A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Res 18:31CrossRef Tan WJ, Cima I, Choudhury Y et al (2016) A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Res 18:31CrossRef
7.
Zurück zum Zitat Vidal M, Peg V, Galván P et al (2015) Gene expression-based classification of fibroadenoma and phyllodes tumours of the breast. Mol Oncol 9:1081–1090CrossRef Vidal M, Peg V, Galván P et al (2015) Gene expression-based classification of fibroadenoma and phyllodes tumours of the breast. Mol Oncol 9:1081–1090CrossRef
8.
Zurück zum Zitat Md Nasir ND, Ng CCY, Rajasegaran V et al (2019) Genomic characterization of breast fibroepithelial lesions in an international cohort. J Pathol 249:447–460CrossRef Md Nasir ND, Ng CCY, Rajasegaran V et al (2019) Genomic characterization of breast fibroepithelial lesions in an international cohort. J Pathol 249:447–460CrossRef
9.
Zurück zum Zitat Li J, Tsang JY, Chen C et al (2019) Predicting outcome in mammary phyllodes tumors: relevance of clinicopathological features. Ann surg oncol 26:2447–2758 Li J, Tsang JY, Chen C et al (2019) Predicting outcome in mammary phyllodes tumors: relevance of clinicopathological features. Ann surg oncol 26:2447–2758
10.
Zurück zum Zitat Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233CrossRef Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233CrossRef
11.
Zurück zum Zitat Macfarlane LA, Murphy PR (2010) MicroRNA: biogenesis, function and role in cancer. Curr Genom 11:537–561CrossRef Macfarlane LA, Murphy PR (2010) MicroRNA: biogenesis, function and role in cancer. Curr Genom 11:537–561CrossRef
12.
Zurück zum Zitat Tsang JY, Ni YB, Ng EK et al (2015) MicroRNAs are differentially deregulated in mammary malignant phyllodes tumour. Histopathology 67:294–305CrossRef Tsang JY, Ni YB, Ng EK et al (2015) MicroRNAs are differentially deregulated in mammary malignant phyllodes tumour. Histopathology 67:294–305CrossRef
13.
Zurück zum Zitat Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866CrossRef Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866CrossRef
14.
Zurück zum Zitat Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259–269CrossRef Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259–269CrossRef
15.
Zurück zum Zitat Dastmalchi N, Safaralizadeh R, Baradaran B et al (2020) An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer. Gene 729:144301CrossRef Dastmalchi N, Safaralizadeh R, Baradaran B et al (2020) An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer. Gene 729:144301CrossRef
16.
Zurück zum Zitat Yu F, Yao H, Zhu P et al (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109–1123CrossRef Yu F, Yao H, Zhu P et al (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109–1123CrossRef
17.
Zurück zum Zitat Tang W, Yu F, Yao H et al (2014) miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 33:2629–2638CrossRef Tang W, Yu F, Yao H et al (2014) miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 33:2629–2638CrossRef
18.
Zurück zum Zitat Gong C, Nie Y, Qu S et al (2014) miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. Can Res 74:4341–4352CrossRef Gong C, Nie Y, Qu S et al (2014) miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. Can Res 74:4341–4352CrossRef
19.
Zurück zum Zitat Li Y, Chen D, Jin L et al (2016) MicroRNA-20b-5p functions as a tumor suppressor in renal cell carcinoma by regulating cellular proliferation, migration and apoptosis. Mol Med Rep 13:1895–1901 CrossRef Li Y, Chen D, Jin L et al (2016) MicroRNA-20b-5p functions as a tumor suppressor in renal cell carcinoma by regulating cellular proliferation, migration and apoptosis. Mol Med Rep 13:1895–1901 CrossRef
20.
Zurück zum Zitat Bertoli G, Cava C, Castiglioni I (2015) MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5:1122–1143 CrossRef Bertoli G, Cava C, Castiglioni I (2015) MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5:1122–1143 CrossRef
21.
Zurück zum Zitat Guo J, Xiao Z, Yu X et al (2017) miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer. Oncol Lett 14:6895–6900PubMedPubMedCentral Guo J, Xiao Z, Yu X et al (2017) miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer. Oncol Lett 14:6895–6900PubMedPubMedCentral
22.
Zurück zum Zitat Liu M, Wang D, Li N (2016) MicroRNA-20b Downregulates HIF-1α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells. Oncol Res 23:257–266CrossRef Liu M, Wang D, Li N (2016) MicroRNA-20b Downregulates HIF-1α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells. Oncol Res 23:257–266CrossRef
23.
Zurück zum Zitat Park SL, Cho TM, Won SY (2015) MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression. Oncol Rep 34:1605–1612CrossRef Park SL, Cho TM, Won SY (2015) MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression. Oncol Rep 34:1605–1612CrossRef
24.
Zurück zum Zitat Wang B, Yang J, Xiao B (2016) MicroRNA-20b(miR-20b) Promotes the Proliferation, Migration, Invasion, and Tumorigenicity in Esophageal Cancer Cells via the Regulation of Phosphatase and Tensin Homologue Expression. PLoS ONE 11:e0164105CrossRef Wang B, Yang J, Xiao B (2016) MicroRNA-20b(miR-20b) Promotes the Proliferation, Migration, Invasion, and Tumorigenicity in Esophageal Cancer Cells via the Regulation of Phosphatase and Tensin Homologue Expression. PLoS ONE 11:e0164105CrossRef
25.
Zurück zum Zitat Katada T, Ishiguro H, Kuwabara Y et al (2009) microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 34:537–542PubMed Katada T, Ishiguro H, Kuwabara Y et al (2009) microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 34:537–542PubMed
26.
Zurück zum Zitat Ahmad A, Ginnebaugh KR, Sethi S et al (2015) miR-20b is up-regulated in brain metastases from primary breast cancers. Oncotarget 6:12188–12195CrossRef Ahmad A, Ginnebaugh KR, Sethi S et al (2015) miR-20b is up-regulated in brain metastases from primary breast cancers. Oncotarget 6:12188–12195CrossRef
27.
Zurück zum Zitat Nozad S, Sheehan CE et al (2017) Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 162:597–602CrossRef Nozad S, Sheehan CE et al (2017) Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 162:597–602CrossRef
28.
Zurück zum Zitat Liu SY, Joseph NM, Ravindranathan A et al (2016) Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol 29:1012–1027CrossRef Liu SY, Joseph NM, Ravindranathan A et al (2016) Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol 29:1012–1027CrossRef
29.
Zurück zum Zitat Li J, Ho WY, Tsang JYS (2019) Expression of biomarkers in AKT pathway correlated with malignancy and recurrence in phyllodes. Histopathology 74:567–577CrossRef Li J, Ho WY, Tsang JYS (2019) Expression of biomarkers in AKT pathway correlated with malignancy and recurrence in phyllodes. Histopathology 74:567–577CrossRef
30.
Zurück zum Zitat He J, Mimi Mu, Luo Y (2019) MicroRNA-20b promotes proliferation of H22 hepatocellular carcinoma cells by targeting PTEN. Oncol Lett 17:2931–2936PubMedPubMedCentral He J, Mimi Mu, Luo Y (2019) MicroRNA-20b promotes proliferation of H22 hepatocellular carcinoma cells by targeting PTEN. Oncol Lett 17:2931–2936PubMedPubMedCentral
Metadaten
Titel
High expression of microRNA20b is associated with malignant clinicopathological features and poor prognosis in breast phyllodes tumor
verfasst von
Ting Lei
Lijuan Yin
Hongying Zhang
Bing Wei
Huijiao Chen
Tianjie Pu
Libo Yang
Feng Ye
Zhang Zhang
Hong Bu
Publikationsdatum
16.08.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 12/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01769-9

Neu im Fachgebiet Onkologie

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.